CRAI — CRA International, Inc.

CRA Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased by 10.8% year-over-year to $185.9 million, marking the best three quarters in CRA's history.
• Profitability: Non-GAAP net income rose by 12.7%, earnings per diluted share increased by 16.4%, and EBITDA grew by 14.6%.
• Utilization Rate: Reached 77%, indicating effective management of resources.
• Legal and Regulatory Services Revenue: Increased by 11.5%, driven by a robust legal market.
• Debt and Liquidity: Concluded the quarter with $22.5 million in cash and $95 million in borrowings, resulting in net debt of $72.5 million. Total liquidity was $123.6 million.

2. Strategic Updates and Business Highlights

• Practice Growth: Seven of eleven practices experienced year-over-year growth, with notable double-digit increases in Antitrust & Competition Economics, energy, finance, and intellectual property.
• International Operations: Revenue from international operations grew by 30.3%, primarily from Antitrust & Competition Economics and Life Sciences practices.
• M&A Activity: CRA's competition practice supported significant merger transactions, including advising UnitedHealth Group on its acquisition of Amedisys.
• Talent Acquisition: CRA welcomed nearly 20 new Vice Presidents, indicating a strategic focus on enhancing leadership and expertise.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised for full fiscal 2025 to a range of $740 million to $748 million, up from a prior range of $730 million to $745 million.
• EBITDA Margin Guidance: Increased lower end of the guidance to a range of 12.6% to 13.0%.
• Market Conditions: Management remains cautious about potential impacts from uncertain global macroeconomic and political conditions.

4. Bad News, Challenges, or Points of Concern

• Headcount Dynamics: A slight year-over-year decrease in total consultant headcount (1.0%) raises questions about staffing levels relative to growth opportunities.
• Days Sales Outstanding (DSO): Increased to 115 days, up from 110 days in the previous quarter, indicating potential cash flow concerns.
• Market Volatility: While current performance is strong, management acknowledged that uncertain conditions could affect future business.

5. Notable Q&A Insights

• Headcount Strategy: Management explained that headcount adjustments are strategic, focusing on growth areas while redeploying resources from less fruitful practices.
• Bill Rate Increases: Confirmed low double-digit growth in bill rates, primarily driven by rate card increases and strong client retention.
• International Growth Drivers: The consistency of regulatory enforcement in Europe compared to the U.S. is contributing to stronger international growth.
• Life Sciences Outlook: While there are signs of improvement, growth remains modest, influenced by complex market dynamics.
• Intellectual Property Demand: The practice is thriving, particularly due to cross-practice collaborations, which often lead to larger, more complex projects.

Overall, CRA's Q3 2025 performance reflects strong growth across multiple practices and regions, bolstered by strategic talent acquisition and effective management. However, challenges such as headcount dynamics and cash flow metrics warrant attention as the company navigates a complex market landscape.